Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus traditionally has been characterized by insulin resistance and β‐cell dysfunction, leading to hyperglycemia and eventual micro‐ and macrovascular complications. Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are a relatively new class of drugs available for the management of type 2 diabetes. In order to provide a comprehensive evaluation and comparison of the pharmacology, pharmacokinetics, efficacy, and safety of the DPP‐4 inhibitors—sitagliptin, vildagliptin, saxagliptin, and alogliptin—in the treatment of type 2 diabetes, we conducted a MEDLINE search (1966–July 2009) for pertinent English‐language articles. Abstracts of the annual meetings of the American Diabetes Association and European Association for the Study of Diabetes from 2005–2009 were also searched. As a drug class, the DPP‐4 inhibitors have become widely accepted in clinical practice because of their low risk of hypoglycemia, favorable adverse‐effect profile, and once‐daily dosing. They are weight neutral (do not cause weight gain or loss) and appear to decrease β‐cell apoptosis and increase β‐cell survival. Because clinical studies directly comparing agents from this class have not, to our knowledge, been conducted, making comparisons in terms of efficacy and safety will become difficult for clinicians as more agents become available. Based on information from preclinical, clinical, and postmarketing data, there does not appear to be a compelling advantage of one DPP‐4 inhibitor over another in terms of efficacy, safety, or ease of clinical use. Although theoretical advantages exist for agents with a higher specificity for DPP‐4 inhibition versus inhibition of other isoenzymes associated with toxicity comparative studies and/or increased clinical experience with this class of drug will determine the clinical advantages, if any, of one agent over another.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“In addition, the benefit of intensive glucose control seems to linger and have positive effects on cardiovascular outcomes and mortality well after clinical trial interventions have ended, as demonstrated in a 10-year follow-up study to the United Kingdom Prospective Diabetes Study (UKPDS).(9) Despite the clear need f…”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Research indicates that GLP-1 also acts centrally within the brain to induce satiety, thus augmenting the beneficial effects of GLP-1 on appetite suppression.(28) In addition, GLP-1 has demonstrated positive effects on -cell prolif-eration, -cell differentiation, and inhibition of -cell apoptosis in animal and in vitr…”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect has been demonstrated to be impaired in people with type 2 diabetes, which may contribute to the inability of these patients to secrete an adequate amount of insulin to meet physiologic needs.(19) The etiology of this deficient incretin response is not entirely understood.”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“The incretin effect has since been identified as being responsible for up to 60% of the insulin response to a given glucose load.(20) The two incretin hormones that attribute to this effect are glucose-dependent insulinotropic peptide (GIP), which is secreted mainly from duodenal K cells of the proximal small bowel, a…”
Background
Cited by
Diabetic peripheral neuropathy: Current perspective and future directions
Singh, R., Kishore, L., & Kaur, N. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.12.005 · Cited by 400
Shah, Z., Kampfrath, T., Deiuliis, J. A., Zhong, J., Pineda, C., Ying, Z., Xu, X., Lu, B., Moffatt-Bruce, S., Durairaj, R., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.041418 · Cited by 377
Monami, M., Ahrén, B., Dicembrini, I., & Mannucci, E. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12000 · Cited by 259
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Pharmacological treatment of diabetes in older people
Valencia, W. M., & Florez, H. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12362 · Cited by 62
Elkhalifa, A. M. E., Nazar, M., Ali, S. I., Khursheed, I., Taifa, S., Ahmad Mir, M., Shah, I. H., Malik, M., Ramzan, Z., Ahad, S., et al. (2024) · Life · doi:10.3390/life14010099 · Cited by 31
Metadata
- Authors
- Neumiller, J. J., Wood, L., & Campbell, R. K.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2010-05
- Volume
- 30
- Issue
- 5
- Pages
- 463-484
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W1991969856
- Cited by
- 150
- References
- 20
- FWCI
- 14.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.